Highlights Four significant microbiome program milestones expected during 2020, including readouts from two late-stage development programs SER-287 Fast Track designation obtained for active mild-to-moderate ulcerative colitis; Phase 2b study enrollment expected to be completed by […]
This month’s 5-minute microbiome science roundup includes some important papers published this month related to both health and disease. The two colorectal cancer microbiome-related papers published in Nature are a sign that the field is beginning […]
The first patient participating in the combination phase I/II study of MRx0518 and *KEYTRUDA® in collaboration with Merck & Co., Inc., Kenilworth, NJ., USA and 4D’s strategic collaboration with MD Anderson has completed Cycle 1 […]
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its Full-Spectrum Microbiota® (FSM®) therapy for the treatment of children […]
Why Phages, and Why Now? Many modern diseases have been linked to alterations in the microbiome and changing it back could be the key to restoring health. Bacteriophages (phages) are viruses that kill bacteria with […]
It is estimated that nearly 3 million newborns and 1.2 million children suffer from sepsis globally each year, with limited effective forms of prevention currently available. To help combat this, DuPont Nutrition & Biosciences (DuPont), […]
This interview was originally published on the Biofortis Mérieux NutriSciences’ Blog. Pr Nicola Segata (Centre for Integrative Biology (CIBIO), University of Trento, Italy) received a €10,000 award from Institut Mérieux, on March 13th at Pharmabiotics 2019 to support his research […]
Biomica, an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), announced the initiation of pre-clinical studies for BMC-121 & BMC-127, two rationally-designed microbial consortia, in its therapeutic […]
Three studies published in the journal Gut over the past 5 years describe how the gut microbiome of African infants is affected not only by dietary iron but also by the combination of iron with antibiotics […]
Kintai is pioneering precision therapeutics based on enteric signaling networks in the human body Flagship Pioneering, a unique life science innovation enterprise, today unveiled Kintai Therapeutics and named Paul-Peter Tak, M.D., Ph.D., as president, chief […]
MaaT Pharma announced that the independent Data and Safety Monitoring Board (DSMB) recommended the continuation, without amendment, of the ongoing Phase II HERACLES study (NCT03359980). The HERACLES trial investigates the use of lead biotherapeutic MaaT013 […]